{"id":"ak120","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"T cell activation-related toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AK120 functions as a bispecific antibody construct that simultaneously binds to CD3 on T cells and to a tumor-associated antigen on cancer cells, bringing them into close proximity. This engagement activates the T cell receptor signaling cascade, enabling T cell proliferation, activation, and direct cytotoxic killing of the targeted cancer cells. The mechanism leverages the patient's own immune system to achieve anti-tumor effects.","oneSentence":"AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:24.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under clinical evaluation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT06700499","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2024-07-08","conditions":"Atopic Dermatitis","enrollment":450},{"nctId":"NCT06035354","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-11-03","conditions":"Atopic Dermatitis","enrollment":427},{"nctId":"NCT05048056","phase":"PHASE2","title":"Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Akesobio Australia Pty Ltd","startDate":"2021-09-30","conditions":"Atopic Dermatitis","enrollment":79},{"nctId":"NCT06767540","phase":"PHASE3","title":"A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-01-23","conditions":"Atopic Dermatitis","enrollment":198},{"nctId":"NCT06756126","phase":"PHASE2","title":"A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2024-12-30","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT06092762","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2023-11-06","conditions":"Atopic Dermatitis","enrollment":180},{"nctId":"NCT06383468","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-04-30","conditions":"Atopic Dermatitis","enrollment":420},{"nctId":"NCT05155020","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma","status":"TERMINATED","sponsor":"Akeso","startDate":"2022-02-11","conditions":"Asthma","enrollment":1},{"nctId":"NCT04256174","phase":"PHASE1","title":"A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Akesobio Australia Pty Ltd","startDate":"2020-06-15","conditions":"Atopic Dermatitis","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AK120","genericName":"AK120","companyName":"Akesobio Australia Pty Ltd","companyId":"akesobio-australia-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens. Used for Solid tumors (specific indication under clinical evaluation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}